Wavemaker 360

VC · (United States)

VC

Pre-Seed

Seed

AI

Cloud/SaaS

Sign up free to access full profile and submit your pitch.

About

Wavemaker Three-Sixty Health (Wavemaker 360) is a Pasadena-based venture capital firm specializing in early-stage healthcare startups. Founded in 2018 by John Nackel, the firm focuses on investing in healthcare disruptors across sectors such as health-tech, digital health, medical devices, telehealth, artificial intelligence, pharma-tech, and marketplaces. Wavemaker 360's investment strategy is centered on identifying and supporting entrepreneurs who are revolutionizing healthcare rather than making incremental improvements. The firm differentiates itself through its extensive network of Limited Partners (LPs), the majority of whom possess significant healthcare industry experience. This network includes healthcare corporates, family offices with healthcare backgrounds, and over 100 individual investors with careers in the healthcare sector. These LPs provide valuable support and resources to portfolio companies, offering access to a wide range of healthcare entities and expertise. As of November 2022, Wavemaker 360 has invested in 50 companies over 50 months, with a portfolio valuation exceeding $2.5 billion. The firm's assets under management (AUM) across two funds total over $85 million. Notable portfolio companies include Trusted Health, Iterative Health, DeepScribe, Carlsmed, Luna, Materna Medical, Ready Set Food!, Regard, Third Eye Health, and Triple Blind. Wavemaker 360 has also achieved successful exits, such as Ciitizen (acquired by Invitae), Alertive (acquired by Carbon Health), and Evid Science (acquired by Genesis Research). The firm's geographic focus spans the United States, Canada, and Southeast Asia, with investments in countries including the U.S., Canada, Europe, and Singapore. Wavemaker 360's mission is to catalyze global healthcare innovation by backing compelling startups that align with its Quintuple Aim framework, which emphasizes improved patient experience, lower costs, new revenue streams for providers, improved clinician experience, and better outcomes.

Investment Criteria